Are Transfusions a Barrier to High-Quality End-of-Life Care in Hematology?
Dr. LeBlanc and Dr. Litzow take a look at an issue within the field consisting of hematologists referring their patients to hospice late or not at all even when there are s
Remission: More Than Meets the Eye
Dr. Teachey reviews a study that suggests that patients in morphologic remission but with high minimal residual disease have inferior outcomes.
Dr. Maese and Dr. Raetz review several studies that have defined the scope and magnitude of medication nonadherence in childhood ALL including the fact that one-third of ALL relapses are attributed to 6-MP nonadherence. They stress the need for simplification of 6-MP delivery instructions.
Dr. Raetz looks at the use of gemtuzumab ozogamicin (CO) for the treatment of acute myeloid leukemia in adults and children.
Dr. Raetz looks at a study that shows response-based therapy in both children and adults with ETP-ALL is effective.
Dr. Raetz discusses a report that provides important new insight into improving the accuracy of induction response assessment by incorporating MRD.
Dr. Raetz looks at a report that shows that Ph-like ALL is common across the age spectrum.
Drs. Raetz and Kovacsovics cover a trial meant to develop a precision medicine approach for the treatment of AML.
Dr. Raetz reviews changes that have emerged in 2016 in the treatment of acute lymphocytic leukemia for both children and adults.
Dr. Raetz looks at a highly promising new monoclonal antibody therapy for CD22-positive B-cell acute lymphoblastic leukemia.
Dr. Raetz looks at the possibility of therapy reduction in carefully defined good risk subsets due to improvements in acute lymphoblastic leukemia outcomes.
Dr. Raetz compares dexamethasone and prednisone for the induction phase of treatment of childhood acute lymphocytic leukemia.
July-August 2018Volume 15, Issue 4
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology